InstalabAlzheimer’s LINX
Should you take a Alzheimer’s LINX test?
This test is most useful if any of these apply to you.
30 biomarkers included
- Tau Protein IgGTargets the tangle-forming protein central to Alzheimer's, probing how your immune system handles a core brain protein.An elevated result may flag altered immune handling of tau, one exploratory signal in the panel's brain-protein group.
- Amyloid-Beta Peptide IgGTracks antibodies to the plaque-forming peptide at the center of the amyloid theory of Alzheimer's.A shift here is proposed to mark changed immune clearance of amyloid, though this remains exploratory, not diagnostic.
- Rabaptin-5 + Presenilin IgGPresenilin is tied to inherited early Alzheimer's; Rabaptin-5 helps cells recycle proteins. Antibodies here probe that clearance machinery.An abnormal result points to reactivity against proteins in the cell-recycling pathways linked to amyloid processing.
- Alpha-Synuclein IgGTargets the protein that aggregates in Parkinson's and Lewy body dementia, which often overlaps with Alzheimer's pathology.Reactivity suggests the immune signal extends beyond Alzheimer's toward broader neurodegeneration, exploratory in this context.
- Beta-Nerve Growth Factor IgGNerve growth factor keeps memory-related neurons alive, so antibodies against it could interfere with that support in theory.A positive result flags reactivity to a survival signal for the brain cells lost early in Alzheimer's.
- Brain-Derived Neurotrophic Factor IgGThis growth factor supports learning and memory connections; the panel checks whether the immune system is reacting against it.Reactivity is proposed to mark disruption of a key memory-supporting growth signal, exploratory not established.
- Neurotrophins IgGA broader look at antibodies against the family of nerve-nourishing proteins, corroborating the individual growth-factor markers.A positive result widens the picture of immune reactivity against the brain's maintenance and repair signals.
- Somatotropin IgGSomatotropin (growth hormone) influences brain repair and metabolism, adding a hormonal angle to the neurotrophin group.Reactivity suggests immune interference with a hormone tied to tissue maintenance, an exploratory contributor to the panel.
- Enteric Nerve + Vasoactive Intestinal Peptide IgGTargets nerves and a signaling peptide of the gut's own nervous system, a proposed relay in the gut-brain axis.Reactivity here is the panel's link between gut nerve signaling and the brain, exploratory.
- Transglutaminases IgGThese enzymes are the target in celiac disease and appear in both gut and brain tissue.A positive result raises the possibility of gluten-related immune reactivity affecting nerve tissue, warranting celiac-specific testing.
- Oral Pathogens IgGMeasures antibodies to gum-disease bacteria that some studies link to brain inflammation and amyloid.Elevated results reflect immune exposure to periodontal bacteria proposed as one contributor to neuroinflammation.
- Enterococcus faecalis IgGA gut bacterium whose antibodies indicate immune exposure that may accompany a leaky or imbalanced gut barrier.Reactivity is proposed to mark gut-immune activation, part of the panel's broader inflammation backdrop.
- Escherichia coli CDT + Salmonella CDT IgGTargets toxins from gut bacteria that can damage the intestinal barrier.A positive result suggests past gut-toxin exposure tied to barrier injury, an exploratory input to the gut-brain hypothesis.
- Campylobacter jejuni CDT A + B IgGAntibodies to a food-poisoning toxin implicated in lasting gut-barrier and nerve irritation.Reactivity flags immune memory of a gut toxin linked to autoimmune and barrier disruption, exploratory here.
- Herpes Type-1 IgGThe cold-sore virus is the pathogen with the most-studied human link between infection and Alzheimer's risk.A positive result confirms prior herpes exposure, the panel's best-supported infectious risk signal, though not a treatable one.
- Aluminums IgGChecks antibodies to aluminum-bound proteins as a marker of exposure to this common environmental metal.A positive result reflects aluminum exposure; its link to Alzheimer's is unproven in humans and strictly exploratory.
- Dinitrophenyl IgGA chemical tag used to detect immune reactivity to industrial and environmental haptens.Reactivity marks exposure to a class of reactive chemicals, an exploratory toxicant signal without an established Alzheimer's link.
- Ethyl + Methyl Mercury IgGMeasures antibodies to mercury-bound proteins from seafood, dental, and environmental sources.A positive result indicates mercury exposure; a direct Alzheimer's connection is not established in human evidence.
- Phthalates IgGPhthalates are plasticizers found in packaging and cosmetics; this checks immune reactivity to them.Reactivity reflects plastic-chemical exposure, an exploratory toxicant marker with no proven human Alzheimer's link.
- Egg Yolk, Raw + Cooked IgGA common dietary antibody whose pattern helps map diet-driven immune reactivity that may accompany gut-barrier changes.A positive result marks immune reactivity to egg, one input to the panel's dietary-immune map.
- Lentil Lectin + Pea Lectin IgGLectins are plant proteins that can bind the gut lining, so antibodies suggest reactivity to legume components.Reactivity is proposed to reflect gut exposure to lectins that may irritate the intestinal barrier, exploratory.
- Tuna, Canned IgGTracks immune reactivity to a common seafood, contributing to the panel's picture of diet-driven immune activation.A positive result flags reactivity to canned tuna within the broader dietary-immune pattern.
- Hazelnut Vicilin + Cashew Vicilin IgGVicilins are tree-nut storage proteins; antibodies map reactivity to these common foods.Reactivity adds tree-nut proteins to the panel's survey of diet-driven immune responses, exploratory.
- Scallops + Squid IgGShellfish antibodies extend the dietary map to another commonly reactive food group.A positive result marks immune reactivity to mollusk seafood within the diet-immune pattern.
- Caseins IgGCasein is the main dairy protein; antibodies are among the most common food reactions and may track gut-barrier activation.Reactivity flags a dairy-protein immune response, one of the diet signals tied to gut permeability.
- Alpha-Gliadin + Gliadin Toxic Peptide IgGGliadin is the wheat protein that drives zonulin release and gut leakiness, the clearest dietary permeability mechanism.A positive result is the panel's strongest dietary link to gut-barrier opening and warrants celiac evaluation.
- Non-Gluten Wheat Proteins IgGCaptures reactivity to wheat proteins beyond gluten, broadening the wheat-immune picture.Reactivity suggests wheat sensitivity outside classic gluten pathways, an exploratory contributor to gut-immune activation.
- Blood-Brain Barrier Protein + Claudin-5 IgGClaudin-5 seals the barrier protecting the brain, so antibodies are proposed to mark a breach in that barrier.A positive result is the panel's central signal of possible blood-brain barrier disruption, exploratory but mechanistically important.
- Aquaporins IgGAquaporins are water channels on barrier-supporting brain cells, extending the barrier-integrity assessment.Reactivity corroborates the barrier signal, pointing to immune reactivity against brain-fluid regulation, exploratory.
- Neurofilament Proteins IgGNeurofilaments are the internal scaffolding of nerve fibers, whose fragments rise when neurons are injured.Elevated antibodies are proposed to reflect ongoing nerve-fiber injury, a general neurodegeneration marker rather than Alzheimer's specifically.
About Alzheimer’s LINX
Alzheimer's disease begins in the brain more than a decade before the first missed word or misplaced key. That long silent window is exactly where a blood test could matter most, if it can read the earliest biological signals.
This panel takes an unconventional approach to that window. Instead of measuring brain proteins directly, it measures your immune system's antibodies against them, plus antibodies to gut, dietary, infectious, and environmental targets, to sketch a wide picture of immune reactivity that researchers are still working to connect to brain aging.
Where This Panel Sits Today
This is an exploratory panel, used mainly in research and functional medicine settings. No major medical society recommends it, and standardized cutoffs for interpreting its results do not yet exist. The blood tests with firmer validation for Alzheimer's measure phosphorylated tau, the amyloid ratio, and neurofilament directly, not antibodies against them.
That does not make the panel useless. It means results should be treated as early, hypothesis-generating signals to explore with a clinician, not as a verdict. Read that way, the combination can point toward avenues worth investigating that no single test would surface.
What This Panel Reveals
The core idea is that neurodegeneration is not one process but several overlapping ones, and that your immune system may leave fingerprints across all of them. Antibodies (a type of immune protein called immunoglobulin G, or IgG) can help clear damaged proteins, so unusual antibody patterns are proposed to mark trouble with that clearance. The panel groups its 30 markers into distinct stories.
The brain-protein markers target the usual suspects of neurodegeneration: the tangle protein tau, the plaque peptide amyloid-beta, the Parkinson's-linked alpha-synuclein, and the nerve-fiber scaffolding neurofilament. In research cohorts, multi-antibody signatures against such proteins have separated Alzheimer's from other conditions. One study of 1,686 people built a seven-antibody signature with an area under the curve of 0.94 (where 1.0 is perfect discrimination and 0.5 is a coin flip). A separate eight-antibody panel detected Alzheimer's-related pathology with 81.0% accuracy on its own, rising to 93.0% when age was added. These signatures come from separate research cohorts and have not been independently replicated; a 2025 review cautioned that reported Alzheimer's autoantibodies differ substantially between studies and some may prove to be false discoveries.
A second group looks at the brain's protective wall. Antibodies to claudin-5 and aquaporins are proposed to mark a leak in the blood-brain barrier, the tight seal that normally keeps blood proteins out of brain tissue. Human imaging studies show this barrier can break down early in cognitive decline, sometimes independent of amyloid and tau, which is why immune reactivity to barrier proteins is of interest even though these specific antibodies are not yet validated.
A third group covers the gut-brain and exposure axis: antibodies to gut nerves and signaling peptides, gut bacteria and their toxins, the cold-sore virus, dietary proteins like gliadin and casein, and environmental chemicals. The most studied human link here is the cold-sore virus. In one large case-control study, people diagnosed with herpes simplex type 1 were about 1.8 times as likely to be diagnosed with Alzheimer's (adjusted odds ratio 1.80, 95% confidence interval 1.65 to 1.96), and those who took antiviral medication were less likely to develop it (adjusted hazard ratio 0.83, 95% confidence interval 0.74 to 0.92). Pooled estimates across many studies are more modest, with meta-analyses reporting odds ratios closer to 1.3 to 1.5. And the one completed randomized trial of the antiviral valacyclovir in people with early Alzheimer's found no cognitive benefit, so this epidemiological link has not yet translated into a proven treatment. The dietary and toxin arms are more conceptual: food antibodies track with gut-barrier immune activation, but no human study shows they predict dementia, and the aluminum, mercury, and phthalate links to Alzheimer's remain unproven in people.
How to Read Your Results Together
The value of a panel is in the pattern, not any one line. Because so many of these antibodies also appear in healthy people, a single positive result means little. Clustering across groups is what draws attention.
| Pattern | What It Suggests |
|---|---|
| Multiple brain-protein antibodies elevated (tau, amyloid-beta, neurofilament) | The strongest signal the panel offers; worth pairing with validated tests like p-tau217 and an amyloid ratio. |
| Barrier antibodies (claudin-5, aquaporins) plus brain-protein antibodies | A proposed barrier-breach pattern; explore vascular and blood-pressure risk factors with a clinician. |
| Gut, dietary, and toxin antibodies elevated but brain markers quiet | Points to a gut-immune or exposure story, not neurodegeneration; investigate gut and diet, not the brain. |
| One isolated positive with everything else normal | Likely background reactivity; a positive antibody alone does not indicate disease. |
What to Do with Your Results
Bring any concerning pattern to a physician, ideally one comfortable with cognitive health. If the brain-protein group is broadly elevated, the logical next step is a validated blood test such as p-tau217 or an amyloid-beta 42/40 ratio, which have a firmer evidence base and can be discussed against the newest Alzheimer's Association guidance. That guidance reserves even validated blood tests for people with cognitive symptoms and does not endorse antibody or food-sensitivity panels for screening.
If the gut and dietary markers dominate, an intestinal permeability workup and celiac testing are more relevant than a brain evaluation, especially when gliadin or transglutaminase antibodies are positive. Because this panel is exploratory, serial tracking is best used to watch trends rather than to trigger alarm; retest annually if you are actively managing your health and want to see whether patterns shift with your interventions.
When Results Can Be Misleading
Naturally occurring brain-reactive antibodies are common in healthy people. In large studies, roughly 10% of people carried antibodies to one brain receptor alone, and across more than 7,000 subjects, antibody presence, class, and titer by themselves did not predict disease. Antibody levels also rise with age regardless of health.
Food and toxin antibodies carry their own trap. Food antigens trigger detectable IgG in up to half of people, so a long list of dietary positives often reflects normal exposure, not harm. Treating any single positive as a diagnosis is the central misconception this panel invites, and the reason interpretation belongs with a clinician who can weigh it against symptoms and validated markers.